JP2014506132A - 抗ｉｌ−１２／ｉｌ−２３抗体およびその使用 - Google Patents

抗ｉｌ−１２／ｉｌ−２３抗体およびその使用 Download PDF

Info

Publication number
JP2014506132A
JP2014506132A JP2013548585A JP2013548585A JP2014506132A JP 2014506132 A JP2014506132 A JP 2014506132A JP 2013548585 A JP2013548585 A JP 2013548585A JP 2013548585 A JP2013548585 A JP 2013548585A JP 2014506132 A JP2014506132 A JP 2014506132A
Authority
JP
Japan
Prior art keywords
amino acid
acid residue
antibody
seq
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013548585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506132A5 (2
Inventor
ボルハニ，デイビツド・ダブリユ
サデユカーン，ラムクリシユナ
レイシー，スーザン・イー
スツター，ホリー・エイチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2014506132A publication Critical patent/JP2014506132A/ja
Publication of JP2014506132A5 publication Critical patent/JP2014506132A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013548585A 2011-01-07 2012-01-06 抗ｉｌ−１２／ｉｌ−２３抗体およびその使用 Pending JP2014506132A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161460780P 2011-01-07 2011-01-07
US61/460,780 2011-01-07
PCT/US2012/020529 WO2012094623A2 (en) 2011-01-07 2012-01-06 Anti-il-12/il-23 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2014506132A true JP2014506132A (ja) 2014-03-13
JP2014506132A5 JP2014506132A5 (2) 2015-02-26

Family

ID=46457988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013548585A Pending JP2014506132A (ja) 2011-01-07 2012-01-06 抗ｉｌ−１２／ｉｌ−２３抗体およびその使用

Country Status (13)

Country Link
US (1) US20120288494A1 (2)
EP (1) EP2661448A4 (2)
JP (1) JP2014506132A (2)
KR (1) KR20140038369A (2)
CN (1) CN103596978A (2)
AU (1) AU2012204237A1 (2)
BR (1) BR112013017417A2 (2)
CA (1) CA2821926A1 (2)
MX (1) MX2013007904A (2)
RU (1) RU2013136908A (2)
SG (1) SG191874A1 (2)
TW (1) TW201242976A (2)
WO (1) WO2012094623A2 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022544050A (ja) * 2019-07-30 2022-10-17 アケソ・バイオファーマ・インコーポレイテッド 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI456062B (zh) 2006-09-13 2014-10-11 Abbvie Inc 細胞培養改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
EP2274333A4 (en) 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
KR20150128859A (ko) * 2013-03-15 2015-11-18 암젠 인크 항-il23 항체를 사용하여 크론병을 치료하는 방법
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN105749252B (zh) * 2016-04-29 2025-11-14 南方医科大学 Il-9作为治疗血小板缺少症的药物的应用
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112232A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
CN117659188A (zh) * 2022-09-07 2024-03-08 南京融捷康生物科技有限公司 一种il-12的单域抗体及其用途
IL320154A (en) * 2022-10-17 2025-06-01 Rani Therapeutics Llc Ustekinumab dosage forms and methods
EP4649088A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2025255560A1 (en) * 2024-06-07 2025-12-11 Rush University Medical Center Intranasal p40 monomer and anti-p40 homodimer mab for type 1 diabetes
WO2026062296A1 (en) * 2024-09-23 2026-03-26 Ose Immunotherapeutics Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523842A (ja) * 2004-12-21 2008-07-10 セントカー・インコーポレーテツド 抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途
JP2009504191A (ja) * 2005-08-19 2009-02-05 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
JP3579355B2 (ja) * 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド ヒトの乾癬を予防及び治療するための乾癬モデル動物
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
EP1623011B1 (en) * 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2205276A4 (en) * 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523842A (ja) * 2004-12-21 2008-07-10 セントカー・インコーポレーテツド 抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途
JP2009504191A (ja) * 2005-08-19 2009-02-05 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEYER, B., ET AL.: "Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affin", JOURNAL OF MOLECULAR BIOLOGY, vol. 382, JPN6015043174, 2008, pages 942 - 955, XP026805072, ISSN: 0003182885, DOI: 10.1016/j.jmb.2008.08.001 *
LUO, J., ET AL.: "Structural Basis for the Dual Recognition of IL-12 and IL-23 by Ustekinumab", JOURNAL OF MOLECULAR BIOLOGY, vol. 402, JPN6015043173, 2010, pages 797 - 812, XP027375322, ISSN: 0003182884, DOI: 10.1016/j.jmb.2010.07.046 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022544050A (ja) * 2019-07-30 2022-10-17 アケソ・バイオファーマ・インコーポレイテッド 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
JP7638955B2 (ja) 2019-07-30 2025-03-04 中山康方生物医▲藥▼有限公司 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
JP2025081517A (ja) * 2019-07-30 2025-05-27 中山康方生物医▲藥▼有限公司 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
US12595300B2 (en) 2019-07-30 2026-04-07 Akeso Biopharma, Inc. Anti-human P40 protein domain antibody and use thereof

Also Published As

Publication number Publication date
SG191874A1 (en) 2013-08-30
CA2821926A1 (en) 2012-07-12
BR112013017417A2 (pt) 2016-09-27
WO2012094623A3 (en) 2012-08-30
EP2661448A2 (en) 2013-11-13
MX2013007904A (es) 2013-08-29
TW201242976A (en) 2012-11-01
EP2661448A4 (en) 2015-09-16
CN103596978A (zh) 2014-02-19
KR20140038369A (ko) 2014-03-28
WO2012094623A2 (en) 2012-07-12
NZ611840A (en) 2015-04-24
US20120288494A1 (en) 2012-11-15
AU2012204237A1 (en) 2013-07-04
RU2013136908A (ru) 2015-02-20

Similar Documents

Publication Publication Date Title
JP2014506132A (ja) 抗ｉｌ−１２／ｉｌ−２３抗体およびその使用
US12077580B2 (en) Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders
AU2008337517B2 (en) Antibodies against human NKG2D and uses thereof
AU2016270640B2 (en) Anti-CD40 antibodies and uses thereof
US10759854B2 (en) Interferon alpha and omega antibody antagonists
TW202043279A (zh) 抗IL-7Rα次單元之抗體及其用途
JP2019522961A (ja) Ｔｌ１ａ抗体およびその使用
US20170291939A1 (en) Antibodies specific for il-17a fused to hyaluronan binding peptide tags
CN104829716A (zh) 用于治疗疾病的抗人sema4A抗体
TW202334220A (zh) 人類腫瘤壞死因子α抗體
NZ611840B2 (en) Anti-il-12/il-23 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150105

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160329